TABLE 2

Pretherapeutic Imaging and Radionuclide Therapy Characteristics

Patient	Group	Age (y)	Sex	Primary tumor	Pretherapeutic imaging			Radionuclide therapy					Follow-up (mo)
Patient	Group	Age (y)	Sex	Primary tumor						¹¹¹In-Pentetreotide uptake (grade)	¹³¹I-MIBG uptake (grade)	Tracer	Follow-up (mo)	Administered activity (GBq)	Number of treatment^†
1	A	63	F	Carcinoid	3	0	¹¹¹In-Pentetreotide	20.0	1	17
2	A	53	M	NET	3	1	¹¹¹In-Pentetreotide	22.1	1	23
3	A	57	M	Carcinoid	4	0	¹¹¹In-Pentetreotide	17.2	1	20
4	A	52	F	Carcinoid	4	0	¹¹¹In-Pentetreotide	19.7	2	57
5	A	56	M	Carcinoid	3	2	¹¹¹In-Pentetreotide	20.6	2	55
6	A	59	M	Carcinoid	3	1	¹¹¹In-Pentetreotide	21.4	2	55
7	A	64	M	NET	3	0	¹¹¹In-Pentetreotide	20.2	1	42
8	A	64	F	NET	3	0	¹¹¹In-Pentetreotide	20.3	1	36
9	A	71	M	Vipoma	3	0	¹¹¹In-Pentetreotide	21.5	1	11
10	A	66	F	Carcinoid	3	0	¹¹¹In-Pentetreotide	20.8	1	5
11	A	80	M	Carcinoid	3	1	¹¹¹In-Pentetreotide	20.4	1	24
12	A	57	M	NET	4	2	¹¹¹In-Pentetreotide	21.4	1	7
13	A	68	F	Carcinoid	3	3	¹³¹I-MIBG	5.8	0.66	22
14	A	62	F	Carcinoid	3	3	¹³¹I-MIBG	18.7	1	28
15	A	49	M	NET	3	3	¹³¹I-MIBG	12.9	1	15
16	A	68	M	Gastrinoma	3	2	¹¹¹In-Pentetreotide	22.5	1	22
17	A	61	F	Carcinoid	3	1	¹¹¹In-Pentetreotide	21.6	1	12
18	A	53	M	Carcinoid	3	3	¹³¹I-MIBG	20.5	1	41
19	A	70	F	NET	3	3	¹³¹I-MIBG	14.3	1	12
20*	A	37	M	Vipoma	4	2	¹¹¹In-Pentetreotide	13.1	0.66	0
Mean ± SD				—	—	—	—	18.8 ± 4.2	—	26.5 ± 16.5
21	B	62	M	Gastrinoma	3	0	—	0	0	2
22	B	74	F	Carcinoid	3	2	—	0	0	1.5
23	B	40	F	Gastrinoma	4	1	—	0	0	10
24	B	58	M	Gastrinoma	3	1	—	0	0	12
25	B	79	M	NET	0	0	—	0	0	8
26	B	50	F	Gastrinoma	3	0	—	0	0	0.25
27	B	71	M	Glucagonoma	3	0	—	0	0	14
28	B	59	M	Gastrinoma	3	0	—	0	0	8
29	B	67	F	Carcinoid	3	0	—	0	0	15
30	B	65	F	Gastrinoma	3	0	—	0	0	15
31	B	81	F	Carcinoid	3	3	—	0	0	3
32	B	85	F	Insulinoma	3	0	—	0	0	12
Mean ± SD	—			—	—	—	—			9.9 ± 4.6
P between groups										P = 0.001